Cambridge Vascular Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
J Endovasc Ther. 2009 Dec;16(6):680-9. doi: 10.1583/09-2817.1.
To report a randomized clinical trial designed to determine if remote ischemic preconditioning (IP) has the ability to reduce renal and cardiac damage following endovascular aneurysm repair (EVAR).
Forty patients (all men; mean age 76+/-7 years) with abdominal aortic aneurysms averaging 6.3+/-0.8 cm in diameter were enrolled in the trial from November 2006 to January 2008. Eighteen patients (mean age 74 years, range 72-81) were randomized to preconditioning and completed the full remote IP protocol; there were no withdrawals. Twenty-two patients (mean age 76 years, range 66-80) were assigned to the control group. Remote IP was induced using sequential lower limb ischemia. Serum and urinary markers of renal and cardiac injury were compared between the groups.
Urinary retinol binding protein (RBP) levels increased 10-fold from a median of 235 micromol/L to 2356 micromol/L at 24 hours (p = 0.0001). There was a lower increase in the preconditioned group, from 167 micromol/L to 413 micromol/L at 24 hours (p = 0.04). The median urinary albumin:creatinine ratio was significantly lower in the preconditioned group at 24 hours (5 versus 8.8, p = 0.06). There were no differences in the rates of renal impairment or major adverse cardiac events.
Remote preconditioning reduces urinary biomarkers of renal injury in patients undergoing elective EVAR. This small pilot trial was unable to detect an effect on clinical endpoints; further trials are warranted.
报告一项随机临床试验,旨在确定远程缺血预处理(IP)是否有能力减少血管内动脉瘤修复(EVAR)后肾和心脏损伤。
2006 年 11 月至 2008 年 1 月,共有 40 名(均为男性;平均年龄 76+/-7 岁)腹主动脉瘤患者,平均直径为 6.3+/-0.8cm,参与了该试验。18 名患者(平均年龄 74 岁,范围 72-81 岁)随机分组进行预处理,并完成了完整的远程 IP 方案;无退出。22 名患者(平均年龄 76 岁,范围 66-80 岁)被分配到对照组。使用下肢间歇性缺血诱导远程 IP。比较两组血清和尿液肾和心脏损伤标志物。
尿视黄醇结合蛋白(RBP)水平从中位数 235μmol/L 增加 10 倍至 24 小时时的 2356μmol/L(p=0.0001)。预处理组的增加较低,从 167μmol/L 增加至 24 小时时的 413μmol/L(p=0.04)。预处理组 24 小时时尿白蛋白/肌酐比值明显较低(5 与 8.8,p=0.06)。两组肾功能不全或主要不良心脏事件发生率无差异。
远程预处理可减少择期 EVAR 患者的尿肾损伤生物标志物。这项小型试点试验未能检测到对临床终点的影响;需要进一步的试验。